🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Haleos Labs Limited HALEOSLABS NSEPHARMA

Healthcare · Biotechnology · India
https://haleoslabs.com

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.

READ MORE ›
₹1,581.30
+15.28% 1Y

Market & Price

Market Cap
₹478.07 Cr
Current Price
₹1,581.30
High / Low (52W)
₹1,690.10 / ₹1,077.45
Beta
0.32

Valuation

Stock P/E
24.10
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹682.92
Price to Book
2.32
P/S
1.37
EV/EBITDA
12.25
Dividend Yield
0.09%

Profitability & Returns

ROCE
13.98%
ROE
-
ROA
-
Profit Margin
5.71%
Op Margin
10.70%
EPS (Latest Qtr)
₹21.89
EPS (TTM)
₹65.62

Balance Sheet & Liquidity

Debt/Equity
0.31
Quick Ratio
-
Current Ratio
-
Debt
₹69.79 Cr
Total Assets
₹389.99 Cr
Current Assets
₹150.57 Cr
Working Capital
₹8.51 Cr

Ownership

Promoter Holding
74.97%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹562.26 Cr
Total Revenue (TTM)
₹347.77 Cr
EBITDA
₹45.91 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹30.23 L
Gross Margin
37.15%
Payout Ratio
2.28%

Growth (CAGR)

Revenue 5Y
-1.02%
Profit 5Y
-7.40%
Revenue (YoY)
12.00%
Earnings (YoY)
21.10%

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -1.0% CAGR over 5 years.
  • Earnings shrank at -7.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HALEOSLABS Haleos Labs Limited NSEPHARMA 1,581.30 24.10 ₹478.07 Cr 0.09% 13.98% - -1.02% -7.40%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue -84.60 Cr81.17 Cr82.50 Cr81.37 Cr94.78 Cr
Cost of Revenue -53.17 Cr56.32 Cr51.64 Cr48.34 Cr61.14 Cr
Gross Profit -31.43 Cr24.85 Cr30.86 Cr33.03 Cr33.64 Cr
Operating Expenses -22.43 Cr21.14 Cr22.97 Cr23.34 Cr23.50 Cr
Operating Income -9.00 Cr3.71 Cr7.89 Cr9.68 Cr10.14 Cr
EBITDA -12.81 Cr9.51 Cr12.71 Cr13.99 Cr14.23 Cr
Interest Expense -2.14 Cr1.78 Cr1.87 Cr1.62 Cr1.54 Cr
Pretax Income -6.92 Cr3.93 Cr7.02 Cr8.49 Cr8.78 Cr
Tax Provision -2.06 Cr44.58 L2.64 Cr2.07 Cr2.13 Cr
Net Income -5.47 Cr2.97 Cr4.16 Cr6.10 Cr6.62 Cr
Diluted EPS 15.4618.08-13.7520.1921.89

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Revenue 347.30 Cr312.55 Cr299.56 Cr336.78 Cr
Cost of Revenue 259.76 Cr228.00 Cr208.79 Cr219.61 Cr
Gross Profit 87.54 Cr84.55 Cr90.77 Cr117.17 Cr
Operating Expenses 62.89 Cr66.50 Cr74.48 Cr87.04 Cr
Operating Income 24.65 Cr18.05 Cr16.28 Cr30.13 Cr
EBITDA 48.44 Cr33.81 Cr34.74 Cr49.64 Cr
Interest Expense 5.70 Cr6.42 Cr9.95 Cr8.46 Cr
Pretax Income 32.73 Cr16.59 Cr9.85 Cr26.19 Cr
Tax Provision 7.43 Cr5.22 Cr3.52 Cr7.46 Cr
Net Income 25.32 Cr11.46 Cr9.09 Cr20.11 Cr
Diluted EPS 83.7637.9230.0866.51

Compounded Sales Growth

5 Years:-1.02%
1 Year:12.00%

Compounded Profit Growth

5 Years:-7.40%
1 Year:21.10%

Stock Price Performance

1 Year:+15.28%
6 Months:+16.68%
3 Months:+21.64%
1 Month:+9.91%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets 356.75 Cr394.89 Cr391.33 Cr389.99 Cr
Current Assets 156.02 Cr159.12 Cr156.08 Cr150.57 Cr
Cash & Equivalents 98.60 L1.28 Cr56.95 L50.29 L
Inventory 84.81 Cr86.23 Cr81.21 Cr67.40 Cr
Receivables 33.83 Cr46.06 Cr51.35 Cr68.79 Cr
Total Liabilities 191.82 Cr206.67 Cr197.69 Cr177.94 Cr
Current Liabilities 135.44 Cr133.56 Cr145.37 Cr142.07 Cr
Long Term Debt 40.33 Cr54.94 Cr33.15 Cr18.27 Cr
Total Debt 79.60 Cr100.49 Cr100.72 Cr86.41 Cr
Total Equity 152.23 Cr168.61 Cr176.81 Cr196.56 Cr
Shares Outstanding 30.23 L30.23 L30.23 L30.23 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow -11.24 Cr14.70 Cr24.31 Cr34.05 Cr
Investing Cash Flow -7.14 Cr-31.29 Cr-18.45 Cr-15.00 Cr
Financing Cash Flow 10.83 Cr16.89 Cr-6.56 Cr-19.12 Cr
Capital Expenditure -51.15 Cr-48.55 Cr-20.87 Cr-15.35 Cr
Free Cash Flow -62.39 Cr-33.86 Cr3.44 Cr18.71 Cr
Net Change in Cash -7.55 Cr29.18 L-70.84 L-6.65 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025
Gross Margin % 25.2%27.1%30.3%34.8%
Operating Margin % 7.1%5.8%5.4%8.9%
Net Margin % 7.3%3.7%3.0%6.0%
ROE % 16.6%6.8%5.1%10.2%
ROCE % 11.1%6.9%6.6%12.2%

Shareholding Pattern

Insiders
74.97%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HALEOSLABS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space